s6 universal m2 immunospot analyzer (Cellular Technology Ltd)
Cellular Technology Ltd is a verified supplier 
Cellular Technology Ltd manufactures this product 
99
Structured Review
Cellular Technology Ltd
s6 universal m2 immunospot analyzer
S6 Universal M2 Immunospot Analyzer, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 85 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s6+universal+m2+immunospot+analyzer/S6+Universal+M2/pmc12889121-194-7-10
Average 99 stars, based on 85 article reviews
S6 Universal M2 Immunospot Analyzer, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 85 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s6+universal+m2+immunospot+analyzer/S6+Universal+M2/pmc12889121-194-7-10
Average 99 stars, based on 85 article reviews
s6 universal m2 immunospot analyzer - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
other:Article Title: Corrected and republished from: "Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis". Article Snippet: Plates were scanned and counted on the Article Title: Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks from 2021-2023 Article Snippet: Plates were scanned and counted on the Article Title: Delineation of the antibody light chain biases and kinetics following primary and secondary influenza virus infections of ferrets. Article Snippet: Spots per well were quantified using an Article Title: Correlates of risk of respiratory syncytial virus disease: a prospective cohort study Article Snippet: Plates were scanned and counted on the Article Title: Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis. Article Snippet: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization in infants and the elderly.. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened interest in RSV immuno logic surveillance, necessitating the development of high-throughput assays assessing anti-RSV neutralizing activity.. Quantitative viral neutralization remains the best correlate of protection for RSV infection and the gold standard for RSV immunological testing. Article Title: Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis Article Snippet: Plates were scanned and counted on the Article Title: Corrected and republished from: “Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis” Article Snippet: Plates were scanned and counted on the Article Title: Delineation of the antibody light chain biases and kinetics following primary and secondary influenza virus infections of ferrets Article Snippet: Spots per well were quantified using an |